Bioanalytical assay for the quantification of the tyrosine kinase inhibitor EAI045 and its major metabolite PIA in mouse plasma and tissue homogenates using liquid chromatography–tandem mass spectrometry

EAI045 is a tyrosine kinase inhibitor (TKI) that targets the mutant epidermal growth factor receptor (EGFR). It was developed to control resistance to available EGFR TKIs. In this study, a major metabolite of EAI045, (5‐fluoro‐2‐hydroxyphenyl)(1‐oxo‐1,3‐dihydro‐2H‐isoindol‐2‐yl)acetic acid (PIA), wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Susam, M. Merve, Wang, Jing, Schinkel, Alfred H., Beijnen, Jos H., Sparidans, Rolf W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786734/
https://www.ncbi.nlm.nih.gov/pubmed/35855648
http://dx.doi.org/10.1002/bmc.5457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786734/
https://www.ncbi.nlm.nih.gov/pubmed/35855648
http://dx.doi.org/10.1002/bmc.5457

Ejemplares similares